New updates have been reported about Sequel Med Tech.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sequel Med Tech has begun full U.S. rollout of its twiist automated insulin delivery system integrated with Senseonics’ Eversense 365, the only continuous glucose monitor approved for one-year implantation. Powered by Tidepool’s algorithm, this makes twiist the first AID platform to work with a year-long CGM, positioning Sequel at the center of a differentiated, long-wear diabetes management offering that reduces sensor replacement and device maintenance burden for type 1 patients.
Strategically, Sequel now gives users a choice between two CGM partners—Eversense 365 and Abbott’s FreeStyle Libre 3 Plus—broadening its addressable market and strengthening its ecosystem positioning in the competitive AID pump segment. The FDA-cleared twiist system, which directly measures every microdose of insulin and uses its proprietary iiSure technology to detect delivery issues faster than rival pumps, is now available by prescription for people six and older and is already in real-world clinical use. This national availability and multi-CGM integration enhance Sequel’s value proposition with payers, providers, and potential partners, and could support future growth as long-term CGMs gain share among intensively managed diabetes patients.